I have changed my sentiment from Sell to Buy on the basis of the following report. Congrats to INSM longs. There is progress, although slow.
From INSM Annual Report:
We have been informed by Premacure that eight infants have been recruited into the trial as of the end of January 28, 2012 and we understand that Premacure plans to accrue up to 95 patients to get 80 evaluable patients in the trial.
at this rate Insmed will be able to get the trial enrolled in the year 2097== has Insmed mentioned Ipplex ever in any conference call or investor presentation Or is this just a useless pump?
It will take time for the PremaCure team to research iPlex for ROP. Long periods of time between results is a reality for any biotech stock. Therefore, they should all be considered speculative and make up only a small portion of a portfolio. Those who follow this little piece of wisdom can use a rational approach to investing instead of emotion.
The increase in dosed premies from 5 to 8 means there is at least some progress versus an end to the investigation. That is good news for INSM.
It took all morning to get my bid price, but I now own INSM shares. I am aware that the share price might decrease when INSM is dropped from the Russell Index in June. However, I plan to hold my current shares for over a year. A paper loss is no big deal. Instead, June will be a buying opportunity.
Jessie - My words were accurate. I said that there was no evidence of progress or additional premies in the Premacure iPlex program. The INSM Annual Report gave me the evidence.
Yes, I am primarily interested in INSM for the ROP indication. The other options are just extra. I pay attention to them, but they do not my main motivation for following INSM.
I spent 20 years working with blind kids; I would love to see ROP prevented.